TY - JOUR
T1 - Oligonucleotide array-cgh identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides
AU - Salgado, Rocío
AU - Servitje, Octavio
AU - Gallardo, Fernando
AU - Vermeer, Maarten H.
AU - Ortiz-Romero, Pablo L.
AU - Karpova, Maria B.
AU - Zipser, Marie C.
AU - Muniesa, Cristina
AU - García-Muret, María P.
AU - Estrach, Teresa
AU - Salido, Marta
AU - Sánchez-Schmidt, Jlia
AU - Herrera, Marta
AU - Romagosa, Vicenç
AU - Suela, Javier
AU - Ferreira, Bibiana I.
AU - Cigudosa, Juan C.
AU - Barranco, Carlos
AU - Serrano, Sergio
AU - Dummer, Reinhard
AU - Tensen, Cornelis P.
AU - Solé, Francesc
AU - Pujol, Ramon M.
AU - Espinet, Blanca
PY - 2010/4/1
Y1 - 2010/4/1
N2 - Mycosis fungoide (MF) patients who develop tumors or extracutaneous involvement usually have a poor prognosis with no curative therapy available so far. In the present European Organization for Research and Treatment of Cancer (EORTC) multicenter study, the genomic profile of 41 skin biopsies from tumor stage MF (MFt) was analyzed using a high-resolution oligo-array comparative genomic hybridization platform. Seventy-six percent of cases showed genomic aberrations. The most common imbalances were gains of 7q33.3q35 followed by 17q21.1, 8q24.21, 9q34qter, and 10p14 and losses of 9p21.3 followed by 9q31.2, 17p13.1, 13q14.11, 6q21.3, 10p11.22, 16q23.2, and 16q24.3. Three specific chromosomal regions, 9p21.3, 8q24.21, and 10q26qter, were defined as prognostic markers showing a significant correlation with overall survival (OS) (P=0.042, 0.017, and 0.022, respectively). Moreover, we have established two MFt genomic subgroups distinguishing a stable group (>0-5 DNA aberrations) and an unstable group (5 DNA aberrations), showing that the genomic unstable group had a shorter OS (P0.05). We therefore conclude that specific chromosomal abnormalities, such as gains of 8q24.21 (MYC) and losses of 9p21.3 (CDKN2A, CDKN2B, and MTAP) and 10q26qter (MGMT and EBF3) may have an important role in prognosis. In addition, we describe the MFt genomic instability profile, which, to our knowledge, has not been reported earlier. © 2010 The Society for Investigative Dermatology.
AB - Mycosis fungoide (MF) patients who develop tumors or extracutaneous involvement usually have a poor prognosis with no curative therapy available so far. In the present European Organization for Research and Treatment of Cancer (EORTC) multicenter study, the genomic profile of 41 skin biopsies from tumor stage MF (MFt) was analyzed using a high-resolution oligo-array comparative genomic hybridization platform. Seventy-six percent of cases showed genomic aberrations. The most common imbalances were gains of 7q33.3q35 followed by 17q21.1, 8q24.21, 9q34qter, and 10p14 and losses of 9p21.3 followed by 9q31.2, 17p13.1, 13q14.11, 6q21.3, 10p11.22, 16q23.2, and 16q24.3. Three specific chromosomal regions, 9p21.3, 8q24.21, and 10q26qter, were defined as prognostic markers showing a significant correlation with overall survival (OS) (P=0.042, 0.017, and 0.022, respectively). Moreover, we have established two MFt genomic subgroups distinguishing a stable group (>0-5 DNA aberrations) and an unstable group (5 DNA aberrations), showing that the genomic unstable group had a shorter OS (P0.05). We therefore conclude that specific chromosomal abnormalities, such as gains of 8q24.21 (MYC) and losses of 9p21.3 (CDKN2A, CDKN2B, and MTAP) and 10q26qter (MGMT and EBF3) may have an important role in prognosis. In addition, we describe the MFt genomic instability profile, which, to our knowledge, has not been reported earlier. © 2010 The Society for Investigative Dermatology.
U2 - 10.1038/jid.2009.306
DO - 10.1038/jid.2009.306
M3 - Article
SN - 0022-202X
VL - 130
SP - 1126
EP - 1135
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 4
ER -
